Pyxis Tankers beat estimated earnings by 5.26%, reporting an EPS of $0.2 versus an estimate of $0.19. Revenue was down $1.50 million from the same period last year. During the previous quarter, the ...
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced ...
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today ...
Pyxis Oncology (NASDAQ:PYXS), a biopharmaceutical company specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment, has been garnering attention from investors and ...
Pyxis Tankers Inc (NASDAQ:PXS) chairman and CEO Valentios (Eddie) Valentis speaks to Thomas Warner from Proactive about how the tanker operator has been performing since his last Proactive appearance ...